Asset
Ranosidenib
HUTCHMED (China) Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04764474 | phase1 | terminated | 2021-04-12 | 2025-01-15 | Hutchmed | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH |
| NCT04762602 | phase1 | terminated | 2021-02-28 | 2025-02-27 | Hutchmed | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations |
| NCT04272957 | phase1 | unknown | 2020-05-14 | 2021-06-30 | Hutchison Medipharma Limited | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms |
| NCT07025018 | phase1 | recruiting | 2025-07-15 | 2026-12-01 | Hutchmed | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations |
FDA applications (0)
This company has no applications containing this asset.